HK1208810A1 - C-terminal and central epitope a-beta antibodies - Google Patents

C-terminal and central epitope a-beta antibodies Download PDF

Info

Publication number
HK1208810A1
HK1208810A1 HK15109545.4A HK15109545A HK1208810A1 HK 1208810 A1 HK1208810 A1 HK 1208810A1 HK 15109545 A HK15109545 A HK 15109545A HK 1208810 A1 HK1208810 A1 HK 1208810A1
Authority
HK
Hong Kong
Prior art keywords
terminal
beta antibodies
central epitope
plaques
central
Prior art date
Application number
HK15109545.4A
Other languages
English (en)
Chinese (zh)
Inventor
Manuel Buttini
Ming Chen
Shyra Gardai
Original Assignee
Janssen Alzheimer Immunotherapy
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Alzheimer Immunotherapy, Wyeth Llc filed Critical Janssen Alzheimer Immunotherapy
Publication of HK1208810A1 publication Critical patent/HK1208810A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK15109545.4A 2012-07-03 2013-06-18 C-terminal and central epitope a-beta antibodies HK1208810A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261667891P 2012-07-03 2012-07-03
US61/667,891 2012-07-03
PCT/US2013/046399 WO2014007982A2 (en) 2012-07-03 2013-06-18 C-terminal and central epitope a-beta antibodies

Publications (1)

Publication Number Publication Date
HK1208810A1 true HK1208810A1 (en) 2016-03-18

Family

ID=49882576

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109545.4A HK1208810A1 (en) 2012-07-03 2013-06-18 C-terminal and central epitope a-beta antibodies

Country Status (13)

Country Link
US (1) US20150353631A1 (enExample)
EP (1) EP2869846A4 (enExample)
JP (1) JP2015526409A (enExample)
KR (1) KR20150036163A (enExample)
CN (1) CN105579061A (enExample)
AU (1) AU2013287119A1 (enExample)
BR (1) BR112014033066A2 (enExample)
CA (1) CA2877516A1 (enExample)
HK (1) HK1208810A1 (enExample)
IL (1) IL236549A0 (enExample)
MX (1) MX2014015744A (enExample)
RU (1) RU2014153675A (enExample)
WO (1) WO2014007982A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078121A1 (en) * 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
BR112017001385B1 (pt) 2014-07-22 2023-12-05 Cb Therapeutics, Inc. Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
ES2987034T3 (es) 2014-08-05 2024-11-13 Apollomics Inc Anticuerpos anti-PD-L1
US20180344881A1 (en) * 2015-11-20 2018-12-06 Navidea Biopharmaceuticals, Inc. Formulations for 2-heteroaryl substituted benzofurans
KR102799807B1 (ko) * 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN105542005B (zh) * 2016-02-03 2018-11-09 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
ES2971881T3 (es) 2016-08-19 2024-06-10 Beigene Switzerland Gmbh Combinación de zanubrutinib con un anticuerpo anti-cd20 o anti-pd-1 para su uso en el tratamiento del cáncer
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
CN118382636A (zh) 2021-12-17 2024-07-23 豪夫迈·罗氏有限公司 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9125798A (en) * 1997-08-28 1999-03-16 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
SK288723B6 (sk) * 2000-02-24 2020-01-07 Univ Washington Farmaceutický prostriedok a použitie tohto farmaceutického prostriedku
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
US20060210557A1 (en) * 2005-01-28 2006-09-21 Donna Luisi Stabilized liquid polypeptide formulations
MY167887A (en) * 2005-12-12 2018-09-26 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
US20100239570A1 (en) * 2007-09-13 2010-09-23 Roger Nitsch Moncolonal amyloid beta (abeta) - specific antibody and uses thereof
WO2011133919A1 (en) * 2010-04-22 2011-10-27 Janssen Alzheimer Immunotherapy Use of tau to monitor immunotherapy
WO2011106732A1 (en) * 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy

Also Published As

Publication number Publication date
MX2014015744A (es) 2015-06-05
BR112014033066A2 (pt) 2017-08-01
EP2869846A2 (en) 2015-05-13
KR20150036163A (ko) 2015-04-07
AU2013287119A1 (en) 2015-01-22
WO2014007982A2 (en) 2014-01-09
US20150353631A1 (en) 2015-12-10
WO2014007982A3 (en) 2014-04-03
CN105579061A (zh) 2016-05-11
CA2877516A1 (en) 2014-01-03
IL236549A0 (en) 2015-02-26
EP2869846A4 (en) 2016-01-13
RU2014153675A (ru) 2016-08-27
JP2015526409A (ja) 2015-09-10

Similar Documents

Publication Publication Date Title
HK1208810A1 (en) C-terminal and central epitope a-beta antibodies
WO2014152006A3 (en) Anti-hepcidin antibodies and uses thereof
MX2022002504A (es) Anticuerpos para cd40.
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
HK1259075A1 (zh) Bcma抗体和其用以治疗癌症和免疫病症的用途
WO2014150877A3 (en) Anti-tau antibodies and methods of use
PH12017500864A1 (en) Anti-notch1 antibodies
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
WO2013068563A3 (en) Antibody molecules having specificity for human ox40
NZ707086A (en) Anti-cd40 antibodies and methods of use
EP4406550A3 (en) Antibodies to cd40 with enhanced agonist activity
IN2014DN05885A (enExample)
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
IL222198A0 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
IN2014DN09717A (enExample)
WO2014062659A3 (en) Methods of treating ocular diseases
SI2906209T1 (sl) D-metadon za zdravljenje psihiatričnih simptomov
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
HK1212713A1 (zh) Vegfr1抗體的治療性用途
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
WO2012166659A3 (en) Anti-emr1 antibodies